|View printer-friendly version|
G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress
"These Phase 2 trial data are consistent with previously reported topline findings and demonstrate the multi-lineage myelopreservation benefits of trilaciclib across neutrophils, red blood cells and lymphocytes for patients receiving chemotherapy," said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. "Our analyses of trilaciclib-related immune response supports the hypothesis that trilaciclib has the potential to improve efficacy of chemotherapy/immune checkpoint inhibitor combinations. Chemotherapy/checkpoint combinations are emerging as standard of care in multiple tumor types, and trilaciclib may offer both myelopreservation and survival benefits when added to these regimens. We expect preliminary myelopreservation data from our Phase 2 clinical trial combining trilaciclib with chemotherapy and the checkpoint inhibitor Tecentriq® (atezolizumab) for the treatment of first-line small cell lung cancer later this year."
Details on the presentations are listed below. Both presentations will be available on the Publications page of the company’s website following their presentation at
Title: Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
Presentation Number: 1671P
Session Name:Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Date / Time / Location:
Presenter: Jessica A. Sorrentino, Ph.D. (
Title: Trilaciclib decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
Presentation Number: 1666PD
Session Name:Poster discussion session - Non-metastatic NSCLC and other thoracic malignancies
Date / Time / Location:
For more information about the
Trilaciclib is a first-in-class myelopreservation therapy designed to preserve hematopoietic stem and progenitor cell function, as well as immune system function, during chemotherapy. Trilaciclib is a short-acting intravenous CDK4/6 inhibitor administered prior to chemotherapy and has the potential to significantly improve treatment outcomes.
Trilaciclib is being evaluated in four randomized Phase 2 clinical trials. In
G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, the therapeutic potential of trilaciclib, lerociclib and G1T48, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the
Head of Investor and Public Relations
Source: G1 Therapeutics